FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:492-494 August 14, 1997 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Unstable angina and non–Q-wave myocardial infarction together constitute a formidable medical problem. Remarkable recent advances in our understanding of the pathophysiology of acute coronary syndromes have, thus far, outpaced progress in developing novel effective therapies. The 30-day rate of death or myocardial infarction currently approximates 9.1 percent, despite the best conventional therapy with aspirin and intravenous unfractionated heparin.¹ The resistance of the acute coronary syndromes to treatment is probably related to their heterogeneous pathophysiology and to the fact that both instability of coronary plaques and hypercoagulability persist for several weeks after the initiation of therapy.²

Despite the widespread use of . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Kelly, R V, Steinhubl, S (2005). Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention. Heart 91: iii16-iii19 [Full Text]  
• Alhadi, H.A., Fox, K.A.A. (2004). Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein. QJM 97: 187-198 [Abstract] [Full Text]  
• Armstrong, P. W. (1999). Pursuing Progress in Acute Coronary Syndromes. Circulation 100: 1586-1589 [Full Text]  
• Messmore, H. L. Jr, Kundur, R., Wehrmacher, W., Scanlon, P. (1999). Anticoagulant Therapy of Pregnant Patients with Prosthetic Heart Valves : Rationale for a Clinical Trial of Low Molecular Weight Heparin. CLIN APPL THROMB HEMOST 5: 73-77 [Abstract]  
• Levi, M., Peters, R. J.G., R. Buller, H. (1998). Weight watching in cardiology: low molecular weight heparin for acute coronary syndromes. Cardiovasc Res 37: 564-566 [Full Text]  
• Kearon, C., Baker, B. A., Adelman, M. D., Krulewitz, A., Goodall, A. H., Knight, C., Cohen, M., Armstrong, P. W. (1998). Low-Molecular-Weight Heparin versus Unfractionated Heparin for Unstable Coronary Disease. NEJM 338: 129-131 [Full Text]  
• Altman, R. (1998). Controversies in Antithrombotic Therapy in Cardiovascular Diseases. CLIN APPL THROMB HEMOST 4: 11-24 [Abstract]